Lowest Price Guaranteed From USD 4,899
Published
January 2020
Pages
473
View Count
14302
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The ophthalmic drugs contract manufacturing market is expected to grow from $0.79 billion in 2020 to $1.7 billion by 2030. Ophthalmic diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye and glaucoma, are considered among the leading causes of vision loss across the globe. According to the World Health Organization’s report published in 2019, at least 2.2 billion individuals in the world are reported to be visually impaired. In fact, blindness caused due to multiple reasons, is projected to increase to 75 million affected individuals by 2020. Moreover, current estimates indicate that the total economic burden related to vision loss is expected to reach approximately USD 384 billion by 2030, in the US alone. The rise in incidence and prevalence of chronic eye disorders has prompted the medical research community to actively develop a variety of ophthalmic drugs / therapies. The current ophthalmic diseases treatment landscape is characterized by a number of blockbuster therapies, namely ALPHAGAN®, COSOPT®, LUMIGAN®, PAZEO®, RESTASIS®, TRAVATAN Z®, and XALATAN®, and a robust pipeline of over 400 candidate drugs in various stages of clinical development, designed for the treatment of approximately 1,000 chronic eye disorders.
Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant benefits, which include reduction in capital investment, access to larger production capacities, reductions in time-to-market and also guarantee a significant degree of commercial risk mitigation. Since 2000, more than 75 new ophthalmology focused CMOs have been established. Amidst the tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. This has caused many service providers to actively expand their respective service portfolios, either through strategic acquisitions or facility / capability expansions. Over time, many CMOs / CDMOs claim to have developed end-to-end service capabilities, ranging from drug development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production.
In light of the aforementioned facts, several CMOs based in the Asia-Pacific region (such as India, China and Japan) play a critical role in the global ophthalmic API and FDF manufacturing. We believe that, the changing supply chain scenario due to the recent COVID-19 pandemic is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.
The ‘Ophthalmic Drugs Contract Manufacturing Market, 2020-2030’ report features an extensive study of the contract services market for ophthalmic products and solutions. It is worth mentioning that the study primarily focuses on small molecule active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall ophthalmic drugs market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical, clinical, and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific). To account for the uncertainties associated with the growth of the ophthalmic drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions presented in this study were influenced by inputs (through an industry-wide survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the ophthalmic drugs contract manufacturing market in the mid to long term.
Chapter 3 presents a general overview of the field of ophthalmology, including information on various chronic eye disorder and the economic burden associated with such conditions. Further, it features a detailed discussion on a variety of ophthalmic drug formulations and affiliated primary packaging. It also provides inputs on the various benefits and challenges associated with the aforementioned products across different types of ophthalmic diseases. Further, the chapter features a brief overview of contract manufacturing and a discussion on the need for outsourcing within the ophthalmic drugs market. In addition, it includes a list of commonly outsourced aseptic manufacturing services and highlights the key factors that need to be considered during the selection of potential CMOs, along with information on key challenges that are currently associated within this market. The chapter concludes with a discussion on the key growth drivers and roadblocks related to ophthalmic drugs contract manufacturing, as well as upcoming trends that the field is expected to witness in the coming years.
Chapter 4 provides a comprehensive overview on the global ophthalmic drugs contract manufacturing landscape. It includes information related to over 240 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market based on a number of parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
Chapter 5 features an insightful company competitiveness analysis of both ophthalmic API and drug FDF contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each business operation and geography on the basis of supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications).
Chapter 6 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in North America. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
Chapter 7 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Europe. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
Chapter 8 includes detailed profiles of some of the key players that are active in the ophthalmic drugs contract manufacturing market in Asia-Pacific. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
Chapter 9 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).
Chapter 10 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of ophthalmic drug products. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, using data from both secondary and primary research. It also examines the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
Chapter 11 features a detailed estimate of the annual demand for ophthalmic APIs and drug FDFs (in million liters), offering an informed opinion on the required scale of supply (in terms of ophthalmic drug contract manufacturing services). In order to estimate the annual commercial demand, we considered the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account the ongoing and planned clinical trials.
Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the ophthalmic drugs contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product (APIs and FDFs), [B] type of FDF manufactured (solids, semi-solids, and liquids / suspensions), [C] type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, blister packing, and other forms), [D] scale of manufacturing (preclinical / clinical and commercial), [E] company size (small sized, mid-sized, and large-sized companies), [F] key disease indications (age-related macular degeneration, glaucoma, uveitis, dry eye, and other disease segments), and [G] key geographical regions, covering North America (the US, Canada and Mexico), Europe (the UK, Germany, France, Spain, Italy and rest of Europe), and Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific).
Chapter 13 is a case study comparing the key characteristics of large and small molecule ophthalmic drugs, along with information on the steps involved in their respective manufacturing processes.
Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ophthalmic drugs contract manufacturing market, under a comprehensive SWOT framework.
Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the ophthalmic drugs contract manufacturing market.
Chapter 16 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Rahul Gupta (Chief Executive Officer, Selvok Pharmaceutical), Vivek Partheeban (Chief Operating Officer, Caplin Point Laboratories) and Ashok Partheeban (Director, Latin American Operations, Caplin Point Laboratories), Stuart Smith (Managing Director, Phytex Australia), and Iranna Bavalatti (General Manager, Gland Pharma).
Chapter 17 highlights the emerging trends and potential market drivers for ophthalmic drug contract manufacturers. It highlights the various opportunities associated with the growing ophthalmic drugs / therapies pipeline, increase in outsourcing of aseptic manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
Chapter 18 is an appendix, which provides a comprehensive list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Ophthalmology
3.2.1. Anatomy of the Human Eye
3.2.2. Chronic Eye Conditions and Associated Economic Burden
3.3. Common Ophthalmic Drug Dosage Forms
3.3.1. Types of Oral Drug Formulations
3.3.1.1. Tablets
3.3.1.2. Capsules
3.3.1.3. Eye Supplements
3.3.2. Types of Semi-solid Formulations
3.3.2.1. Ointments
3.5.2.2. Gels
3.5.2.3. Emulsions
3.3.3. Types of Liquid Drug Formulations
3.3.3.1. Solutions
3.3.3.2. Suspensions
3.5.3.1. Sterile Injectables
3.3.4. Intraocular Inserts
3.4. Common Primary Packaging Formats for Ophthalmic Drugs
3.5. Overview of Contract Manufacturing
3.6. Outsourcing in the Ophthalmology Industry
3.6.1. Need for Outsourcing
3.6.2. Commonly Outsourced Operations
3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
3.6.4. Advantages of Outsourcing Manufacturing Operations
3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing
3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
3.6.7. Recent Developments and Upcoming Trends
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Type of FDF Manufactured
4.2.8. Analysis by Type of Primary Packaging
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications
5. COMPANY COMPETITVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers
5.3.1. Ophthalmic API Contract Manufacturers in North America
5.3.2. Ophthalmic API Contract Manufacturers in Europe
5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific
5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers
5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe
5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific
6. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. Akorn
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Catalent
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.4. Cayman Chemical
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Pillar5 Pharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Sterling Pharmaceutical Services
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
7. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES
7.1. Chapter Overview
7.2. FARMIGEA
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Lomapharm
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3 Recent Developments and Future Outlook
7.4. Medichem
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Recipharm
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Service Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Salvat
7.6.1. Company Overview
7.6.2 Service Portfolio
7.6.3. Recent Developments and Future Outlook
8. OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Akums
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Bal Pharma
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.4. Entod Pharmaceuticals
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Glenmark Pharmaceuticals
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. Indiana Ophthalmics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Sunways India
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Ophthalmic Drug Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Geographical Analysis by Number of Clinical Trials
9.3.3. Geographical Analysis by Enrolled Patient Population
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Type of Sponsor / Collaborator
9.3.7. Most Active Players in Terms of Number of Registered Trials
9.3.8. Analysis by Type of Intervention
9.3.9. Analysis by Trial Focus
9.3.10. Analysis by Target Indication
9.3.11. Benchmark Analysis of Active Industry Players
10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity (by Volume)
10.3.1. Analysis by Geography
10.3.1.1. Overall Production Capacity in North America (by Volume)
10.3.1.2. Overall Production Capacity in Europe (by Volume)
10.3.1.3. Overall Production Capacity in Asia-Pacific (by Volume)
10.3.2. Analysis by Scale of Operation
10.3.2.1. Overall Lab Scale Production Capacity (by Volume)
10.3.2.2. Overall Clinical Scale Production Capacity (by Volume)
10.3.2.3. Overall Commercial Scale Production Capacity (by Volume)
10.3.3. Analysis by Company Size
10.3.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
10.3.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
10.3.3.3. Overall Production Capacity of Large-sized Companies (by Volume)
10.4. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity
10.4.1. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Volume)
10.4.1.1. Analysis by Geography
10.4.1.1.1. Overall Production Capacity in North America (by Volume)
10.4.1.1.2. Overall Production Capacity in Europe (by Volume)
10.4.1.1.3. Overall Production Capacity in Asia-Pacific (by Volume)
10.4.1.2. Analysis by Scale of Operation
10.4.1.2.1. Overall Lab Scale Production Capacity (by Volume)
10.4.1.2.2. Overall Clinical Scale Production Capacity (by Volume)
10.4.1.2.3. Overall Commercial Scale Production Capacity (by Volume)
10.4.1.3. Analysis by Company Size
10.4.1.3.1. Overall Production Capacity of Small-sized Companies (by Volume)
10.4.1.3.2. Overall Production Capacity of Mid-sized Companies (by Volume)
10.4.1.3.3. Overall Production Capacity of Large-sized Companies (by Volume)
10.4.1.4. Analysis by Type of Primary Packaging
10.4.1.4.1. Overall Production Capacity of Ampoules / Vials (by Volume)
10.4.1.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Volume)
10.4.1.4.3. Overall Production Capacity of Ointment Tubes (by Volume)
10.4.2. Ophthalmic Drug FDF Contract Manufacturers: Global Production Capacity (by Number of Units)
10.4.2.1. Analysis by Geography
10.4.2.1.1. Overall Production Capacity in North America (by Number of Units)
10.4.2.1.2. Overall Production Capacity in Europe (by Number of Units)
10.4.2.1.3. Overall Production Capacity in Asia-Pacific (by Number of Units)
10.4.2.2. Analysis by Scale of Operation
10.4.2.2.1. Overall Lab Scale Production Capacity (by Number of Units)
10.4.2.2.2. Overall Clinical Scale Production Capacity (by Number of Units)
10.4.2.2.3. Overall Commercial Scale Production Capacity (by Number of Units)
10.4.2.3. Analysis by Company Size
10.4.2.3.1. Overall Production Capacity of Small-sized Companies (by Number of Units)
10.4.2.3.2. Overall Production Capacity of Mid-sized Companies (by Number of Units)
10.4.2.3.3. Overall Production Capacity of Large-sized Companies (by Number of Units)
10.4.2.4. Analysis by Type of Primary Packaging
10.4.2.4.1. Overall Production Capacity of Ampoules / Vials (by Number of Units)
10.4.2.4.2. Overall Production Capacity of Glass / Plastic Bottles (by Number of Units)
10.4.2.4.3. Overall Production Capacity of Ointment Tubes (by Number of Units)
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Global Commercial Demand for Ophthalmic Drugs Contract Manufacturing
11.3.1. Commercial Demand for Ophthalmic API Contract Manufacturing
11.3.1.1. Analysis by Geography
11.3.1.2. Analysis by Scale of Operation
11.3.1.3. Analysis by Target Indication
11.3.2. Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing
11.3.2.1. Analysis by Geography
11.3.2.2. Analysis by Scale of Operation
11.3.2.3. Analysis by Target Indication
11.3.2.4. Analysis by Type of Primary Packaging
11.4. Global Clinical Demand for Ophthalmic Drugs Contract Manufacturing
11.4.1. Clinical Demand for Ophthalmic API Contract Manufacturing
11.4.1.1. Analysis by Geography
11.4.1.2. Analysis by Scale of Operation
11.4.1.3. Analysis by Target Indication
11.4.2. Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing
11.4.2.1. Analysis by Geography
11.4.2.2. Analysis by Scale of Operation
11.4.2.3. Analysis by Target Indication
11.4.2.4. Analysis by Type of Primary Packaging
11.5. Demand and Supply Analysis
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030
12.4. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product
12.4.1. Ophthalmic API Contract Manufacturing Market, 2020-2030
12.4.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030
12.4.2.1. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured
12.4.2.1.1. Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030
12.4.2.1.2. Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030
12.4.2.1.3. Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030
12.4.2.2. Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging
12.4.2.2.1. Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030
12.4.2.2.2. Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030
12.4.2.2.3. Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030
12.4.2.2.4. Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030
12.4.2.2.5. Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030
12.5. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication
12.5.1. Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030
12.5.2. Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030
12.5.3. Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030
12.5.4. Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030
12.5.5. Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030
12.6. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
12.6.1. Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
12.6.2. Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030
12.7. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Size of Manufacturers
12.7.1. Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030
12.7.2. Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030
12.7.3. Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030
12.8. Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions
12.8.1. Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030
12.8.1.1. Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030
12.8.1.2. Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030
12.8.1.3. Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030
12.8.2. Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030
12.8.2.1. Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030
12.8.2.2. Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030
12.8.2.3. Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030
12.8.2.4. Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030
12.8.2.5. Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030
12.8.2.6. Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030
12.8.3. Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030
12.8.3.1. Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030
12.8.3.2. Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030
12.8.3.3. Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030
12.8.3.4. Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030
12.8.3.5. Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030
13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE MOLECULE OPHTHALMIC DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule Drugs and Biologics
13.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Processes
13.2.4. Comparison of Key Manufacturing-related Challenges
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
15. SURVEY ANALYSIS
15.1. Chapter Overview
15.2. Overview of Respondents
15.2.1. Seniority Level of Respondents
15.3. Survey Insights
15.3.1. Type of Product
15.3.2. Type of Primary Packaging
15.3.3. Scale of Operation
15.3.4. Manufacturing Capacity
15.3.5. Location of Manufacturing Facilities
15.3.6. Regulatory Accreditations / Certifications of Manufacturing Facilities
15.3.7. Extent of Outsourcing
15.3.8. Current Market Opportunity
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Selvok Pharmaceutical
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Rahul Gupta, Chief Executive Officer
16.3. Caplin Point Laboratories
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Vivek Partheeban, Chief Operating Officer and Ashok Partheeban, Director, Latin American Operations
16.4. Phytex Australia
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Stuart Smith, Managing Director
16.5. Gland Pharma
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Iranna Bavalatti, General Manager
17. FUTURE GROWTH OPPORTUNITIES
17.1. Chapter Overview
17.2. Integration / Adoption of New and Innovative Technologies
17.3. Capability and Expertise Expansions by CMOs
17.4. Offshoring Outsourcing Activities
17.5. Growing Investments in Existing Infrastructure
17.6. Evolving Client / Sponsor and CMO / CDMO Relationships
17.7. Business Acquisition and Consolidation Activity
17.8. Challenges Faced by Both Sponsors and Service Providers
17.8.1. Concerns Related to Single Use Systems
17.8.2. Concerns Related to Capacity Fluctuations
18. APPENDIX 1: LIST OF OPHTHALMIC MEDICAL DEVICE CONTRACT MANUFACTURERS
19. APPENDIX 2: TABULATED DATA
20 APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
Figure 3.2 Classification of Ophthalmic Drug Dosage Forms
Figure 3.3 Advantages and Disadvantages of Tablets
Figure 3.4 Advantages and Disadvantages of Capsules
Figure 3.5 Advantages and Disadvantages of Eye Supplements
Figure 3.6 Advantages and Disadvantages of Ointments
Figure 3.7 Advantages and Disadvantages of Gels
Figure 3.8 Advantages and Disadvantages of Emulsions
Figure 3.9 Advantages and Disadvantages of Solutions
Figure 3.10 Advantages and Disadvantages of Suspensions
Figure 3.11 Advantages and Disadvantages of Sterile Injectables
Figure 3.12 Advantages and Disadvantages of Intraocular Inserts
Figure 3.13 Common Primary Packaging Formats for Ophthalmic Drugs
Figure 3.14 Types of Standalone Contract Service Providers
Figure 3.15 Outsourcing in the Ophthalmology Industry
Figure 3.16 Commonly Outsourced Operations
Figure 3.17 Guidelines for Selecting a CMO Partner
Figure 3.18 Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
Figure 4.1 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
Figure 4.3 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
Figure 4.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
Figure 4.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
Figure 4.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
Figure 4.10 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
Figure 4.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
Figure 4.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
Figure 4.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
Figure 4.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
Figure 4.15 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 5.1 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in North America
Figure 5.2 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Europe
Figure 5.3 Competitiveness Analysis of Ophthalmic API Contract Manufacturers in Asia-Pacific
Figure 5.4 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in North America
Figure 5.5 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Europe
Figure 5.6 Competitiveness Analysis of Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific
Figure 6.1 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
Figure 6.2 Akorn: Service Portfolio
Figure 6.3 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
Figure 6.4 Catalent: Service Portfolio
Figure 6.5 Cayman Chemical: Service Portfolio
Figure 6.6 Pillar5 Pharma: Service Portfolio
Figure 6.7 Sterling Pharmaceutical Services: Service Portfolio
Figure 7.1 FARMIGEA: Service Portfolio
Figure 7.2 Lomapharm: Service Portfolio
Figure 7.3 Medichem: Service Portfolio
Figure 7.4 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
Figure 7.5 Recipharm: Service Portfolio
Figure 7.6 Salvat: Service Portfolio
Figure 8.1 Akums: Service Portfolio
Figure 8.2 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
Figure 8.3 Bal Pharma: Service Portfolio
Figure 8.4 Entod Pharmaceuticals: Service Portfolio
Figure 8.5 Glenmark Pharmaceuticals: Service Portfolio
Figure 8.6 Indiana Ophthalmics: Service Portfolio
Figure 8.7 Sunways India: Service Portfolio
Figure 9.1 Clinical Trials: Distribution by Trial Recruitment Status
Figure 9.2 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
Figure 9.3 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Figure 9.4 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
Figure 9.5 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
Figure 9.6 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 9.7 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
Figure 9.8 Clinical Trials: Distribution by Phase of Development
Figure 9.9 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
Figure 9.10 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
Figure 9.11 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 9.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 9.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Clinical Trials: Distribution by Type of Intervention
Figure 9.15 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
Figure 9.16 Clinical Trials: Popular Keywords
Figure 9.17 Popular Indications: Distribution by Number of Registered Trials
Figure 9.18 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
Figure 9.19 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
Figure 9.20 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
Figure 9.21 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Figure 10.1 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
Figure 10.2 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
Figure 10.3 Ophthalmic API Production Capacity in North America (Million Liters)
Figure 10.4 Ophthalmic API Production Capacity in Europe (Million Liters)
Figure 10.5 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
Figure 10.6 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
Figure 10.7 Lab Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.8 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.9 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
Figure 10.10 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
Figure 10.11 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
Figure 10.12 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
Figure 10.13 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
Figure 10.14 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
Figure 10.15 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
Figure 10.16 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
Figure 10.17 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
Figure 10.18 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
Figure 10.19 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
Figure 10.20 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.21 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.22 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Figure 10.23 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
Figure 10.24 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
Figure 10.25 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
Figure 10.26 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
Figure 10.27 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
Figure 10.28 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
Figure 10.29 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
Figure 10.30 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
Figure 10.31 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
Figure 10.32 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
Figure 10.33 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
Figure 10.34 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
Figure 10.35 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
Figure 10.36 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
Figure 10.37 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.38 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.39 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Figure 10.40 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
Figure 10.41 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
Figure 10.42 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
Figure 10.43 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
Figure 10.44 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
Figure 10.45 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
Figure 10.46 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
Figure 10.47 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
Figure 11.1 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Figure 11.2 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.3 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.4 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.5 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Figure 11.6 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.7 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.8 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.9 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
Figure 11.10 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Figure 11.11 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.12 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.13 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.14 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Figure 11.15 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Figure 11.16 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Figure 11.17 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Figure 11.18 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
Figure 11.19 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
Figure 12.1 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product (USD Billion)
Figure 12.3 Ophthalmic API Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.4 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.5 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured (USD Billion)
Figure 12.6 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030 (USD Billion)
Figure 12.7 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030 (USD Billion)
Figure 12.8 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030 (USD Billion)
Figure 12.9 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging (USD Billion)
Figure 12.10 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030 (USD Billion)
Figure 12.11 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030 (USD Billion)
Figure 12.12 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030 (USD Billion)
Figure 12.13 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030 (USD Billion)
Figure 12.14 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030 (USD Billion)
Figure 12.15 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication (USD Billion)
Figure 12.16 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030 (USD Billion)
Figure 12.17 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030 (USD Billion)
Figure 12.18 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030 (USD Billion)
Figure 12.19 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030 (USD Billion)
Figure 12.20 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030 (USD Billion)
Figure 12.21 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 12.22 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Billion)
Figure 12.23 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Billion)
Figure 12.24 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 12.25 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Billion)
Figure 12.26 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Billion)
Figure 12.27 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030 (USD Billion)
Figure 12.28 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions (USD Billion)
Figure 12.29 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 12.30 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
Figure 12.31 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
Figure 12.32 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030 (USD Billion)
Figure 12.33 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 12.34 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
Figure 12.35 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
Figure 12.36 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030 (USD Billion)
Figure 12.37 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
Figure 12.38 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
Figure 12.39 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 12.40 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 12.41 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030 (USD Billion)
Figure 12.42 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030 (USD Billion)
Figure 12.43 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
Figure 12.44 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030 (USD Billion)
Figure 12.45 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.1 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
Figure 13.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 13.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 14.1 Ophthalmic Drugs Contract Manufacturing: SWOT Analysis
Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 15.1 Survey Insights: Overview of Respondents
Figure 15.2 Survey Insights: Distribution by Type of Organization
Figure 15.3 Survey Insights: Distribution by Location of Organization
Figure 15.4 Survey Insights: Distribution by Seniority Level
Figure 15.5 Survey Insights: Distribution by Type of Product
Figure 15.6 Survey Insights: Distribution by Type of Primary Packaging
Figure 15.7 Survey Insights: Distribution by Scale of Operation
Figure 15.8 Survey Insights: Distribution by Location of Manufacturing Facilities
Figure 15.9 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
Figure 15.10 Survey Insights: Distribution by Extent of Outsourcing
Table 4.1 Ophthalmic Drug Contract Manufacturers: List of Industry Players
Table 4.2 Ophthalmic Drug Contract Manufacturers: Information on Location of FDF Manufacturing Facilities
Table 4.3 Ophthalmic Drug Contract Manufacturers: Information on Location of API Manufacturing Facilities
Table 4.4 Ophthalmic Drug Contract Manufacturers: Information on Type of FDF Manufactured and Type of Primary Packaging
Table 4.5 Ophthalmic Drug Contract Manufacturers: Information on Type of Service(s) Offered
Table 4.6 Ophthalmic Drug Contract Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1 Akorn: Key Highlights
Table 6.2 Akorn: Manufacturing Capabilities
Table 6.3 Akorn: Recent Developments and Future Outlook
Table 6.4 Catalent: Key Highlights
Table 6.5 Catalent: Recent Developments and Future Outlook
Table 6.6 Cayman Chemical: Key Highlights
Table 6.7 Cayman Chemical: Manufacturing Capabilities
Table 6.8 Cayman Chemical: Recent Developments and Future Outlook
Table 6.9 Pillar5 Pharma: Key Highlights
Table 6.10 Pillar5 Pharma: Recent Developments and Future Outlook
Table 6.11 Sterling Pharmaceutical Services: Key Highlights
Table 6.12 Sterling Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.1 FARMIGEA: Key Highlights
Table 7.2 FARMIGEA: Manufacturing Capabilities
Table 7.3 FARMIGEA: Recent Developments and Future Outlook
Table 7.4 Lomapharm: Key Highlights
Table 7.5 Lomapharm: Recent Developments and Future Outlook
Table 7.6 Medichem: Key Highlights
Table 7.7 Medichem: Manufacturing Capabilities
Table 7.8 Medichem: Manufacturing Locations
Table 7.9 Medichem: Recent Developments and Future Outlook
Table 7.10 Recipharm: Key Highlights
Table 7.11 Recipharm: Manufacturing Locations
Table 7.12 Recipharm: Recent Developments and Future Outlook
Table 7.13 Salvat: Key Highlights
Table 7.14 Salvat: Manufacturing Capabilities
Table 7.15 Salvat: Recent Developments and Future Outlook
Table 8.1 Akums: Key Highlights
Table 8.2 Akums: Recent Developments and Future Outlook
Table 8.3 Bal Pharma: Key Highlights
Table 8.4 Bal Pharma: Recent Developments and Future Outlook
Table 8.5 Entod Pharmaceuticals: Key Highlights
Table 8.6 Entod Pharmaceuticals: Manufacturing Capabilities
Table 8.7 Entod Pharmaceuticals: Recent Developments and Future Outlook
Table 8.8 Glenmark Pharmaceuticals: Key Highlights
Table 8.9 Glenmark Pharmaceuticals: Recent Developments and Future Outlook
Table 8.10 Indiana Ophthalmics: Key Highlights
Table 8.11 Indiana Ophthalmics: Recent Developments and Future Outlook
Table 8.12 Sunways India: Key Highlights
Table 8.13 Sunways India: Recent Developments and Future Outlook
Table 10.1 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
Table 10.2 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.3 Ophthalmic API Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
Table 10.4 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Geography (Sample Data Set)
Table 10.5 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.6 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Company Size (Sample Data Set)
Table 10.7 Ophthalmic Drug FDF Production Capacity (Million Liters): Average Capacity by Type of Primary Packaging (Sample Data Set)
Table 10.8 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Geography (Sample Data Set)
Table 10.9 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Scale of Operation (Sample Data Set)
Table 10.10 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Company Size (Sample Data Set)
Table 10.11 Ophthalmic Drug FDF Production Capacity (Million Units): Average Capacity by Type of Primary Packaging (Sample Data Set)
Table 13.1 Strengths and Weaknesses of Small Molecules and Biologics
Table 13.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 15.1 Survey Insights: Overview of Respondents
Table 15.2 Survey Insights: Seniority Level of Respondents
Table 15.3 Survey Insights: Type of Product
Table 15.4 Survey Insights: Type of Primary Packaging
Table 15.5 Survey Insights: Scale of Operation
Table 15.6 Survey Insights: Manufacturing Capacity
Table 15.7 Survey Insights: Number and Location of Manufacturing Facilities
Table 15.8 Survey Insights: Regulatory Accreditations / Certifications of Manufacturing Facilities
Table 15.9 Survey Insights: Extent of Outsourcing
Table 15.10 Survey Insights: Current Market Opportunity (USD Billion)
Table 16.1 Selvok Pharmaceutical: Key Highlights
Table 16.2 Caplin Point Laboratories: Key Highlights
Table 16.3 Phytex Australia: Key Highlights
Table 16.4 Gland Pharma: Key Highlights
Table 18.1 Ophthalmic Medical Device Contract Manufacturers: List of Industry Players
Table 18.2 Ophthalmic Medical Device Contract Manufacturers: Information on Type of Service(s) Offered and Scale of Operation
Table 18.3 Ophthalmic Medical Device Contract Manufacturers: Information on Additional Service(s) Offered
Table 18.4 Ophthalmic Medical Device Contract Manufacturers: Information on Location of Manufacturing Facilities
Table 18.5 Ophthalmic Medical Device Contract Manufacturers: Information on Device Class and Regulatory Accreditations / Certifications
Table 19.1 Estimates on the Visually Impaired Population (US), 2019, 2030 and 2050 (in Millions)
Table 19.2 Ophthalmic Drug Contract Manufacturers: Distribution by Year of Establishment
Table 19.3 Ophthalmic Drug Contract Manufacturers: Distribution by Company Size
Table 19.4 Ophthalmic Drug Contract Manufacturers: Distribution by Scale of Operation
Table 19.5 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 19.6 Ophthalmic Drug Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 19.7 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Region-Wise)
Table 19.8 Ophthalmic Drug Contract Manufacturers: Distribution by Location of FDF Manufacturing Facilities (Country-Wise)
Table 19.9 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Region-Wise)
Table 19.10 Ophthalmic Drug Contract Manufacturers: Distribution by Location of API Manufacturing Facilities (Country-Wise)
Table 19.11 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Product
Table 19.12 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured
Table 19.13 Ophthalmic Drug Contract Manufacturers: Distribution by Type of FDF Manufactured and Company Size
Table 19.14 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Primary Packaging
Table 19.15 Ophthalmic Drug Contract Manufacturers: Distribution by Type of Service(s) Offered
Table 19.16 Ophthalmic Drug Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Table 19.17 Akorn: Net Revenues, FY 2015-Q3 2019 (USD Million)
Table 19.18 Catalent: Net Revenues, FY 2015-FY 2019 (USD Million)
Table 19.19 Recipharm: Net Revenues, FY 2015-Q3 2019 (SEK Million)
Table 19.20 Bal Pharma: Net Revenues, FY 2015-FY 2019 (INR Million)
Table 19.21 Clinical Trials: Distribution by Trial Recruitment Status
Table 19.22 Clinical Trials: Cumulative Distribution by Trial Registration Year, Pre-2010-Q3 2019
Table 19.23 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Table 19.24 Clinical Trials: Percentage Increase in Number of Trials, Pre- and Post-2010
Table 19.25 Clinical Trials: Distribution by Trial Registration Year and Geography, Pre-2010-2018
Table 19.26 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 19.27 Clinical Trials: Cumulative Distribution by Enrolled Patient Population and Trial Registration Year, Pre-2010-Q3 2019
Table 19.28 Clinical Trials: Distribution by Phase of Development
Table 19.29 Clinical Trials: Distribution by Trial Recruitment Status and Registration Year, Pre-2010-Q3 2019
Table 19.30 Clinical Trials: Geographical Distribution by Trial Recruitment Status and Registration Year, Pre- and Post-2010
Table 19.31 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 19.32 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.33 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.34 Clinical Trials: Distribution by Type of Intervention
Table 19.35 Clinical Trials: Distribution by Type of Intervention and Trial Registration Year, 2010-2018
Table 19.36 Popular Indications: Distribution by Number of Registered Trials
Table 19.37 Clinical Trials: Distribution by Popular Indications and Trial Registration Year, 2010-2018
Table 19.38 Clinical Trials: Distribution by Popular Indications and Type of Trial Sponsor
Table 19.39 Clinical Trials: Distribution by Most Active Industry Players and Trial Registration Year, 2013-2018
Table 19.40 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Table 19.41 Ophthalmic API Contract Manufacturers: Overall Production Capacity (Million Liters)
Table 19.42 Ophthalmic API Production Capacity: Distribution by Geography (Million Liters)
Table 19.43 Ophthalmic API Production Capacity in North America (Million Liters)
Table 19.44 Ophthalmic API Production Capacity in Europe (Million Liters)
Table 19.45 Ophthalmic API Production Capacity in Asia-Pacific (Million Liters)
Table 19.46 Ophthalmic API Production Capacity: Distribution by Scale of Operation (Million Liters)
Table 19.47 Lab Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.48 Clinical Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.49 Commercial Scale Ophthalmic API Production Capacity (Million Liters)
Table 19.50 Ophthalmic API Production Capacity: Distribution by Company Size (Million Liters)
Table 19.51 Ophthalmic API Production Capacity of Small-sized Companies (Million Liters)
Table 19.52 Ophthalmic API Production Capacity of Mid-sized Companies (Million Liters)
Table 19.53 Ophthalmic API Production Capacity of Large-sized Companies (Million Liters)
Table 19.54 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Liters)
Table 19.55 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Liters)
Table 19.56 Ophthalmic Drug FDF Production Capacity in North America (Million Liters)
Table 19.57 Ophthalmic Drug FDF Production Capacity in Europe (Million Liters)
Table 19.58 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Liters)
Table 19.59 Ophthalmic Drug FDF Production Capacity: Distribution by Scale of Operation (Million Liters)
Table 19.60 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.61 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.62 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Liters)
Table 19.63 Ophthalmic Drug FDF Production Capacity: Distribution by Company Size (Million Liters)
Table 19.64 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Liters)
Table 19.65 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Liters)
Table 19.66 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Liters)
Table 19.67 Ophthalmic Drug FDF Production Capacity: Distribution by Type of Primary Packaging (Million Liters)
Table 19.68 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Liters)
Table 19.69 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Liters)
Table 19.70 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Liters)
Table 19.71 Ophthalmic Drug FDF Contract Manufacturers: Overall Production Capacity (Million Units)
Table 19.72 Ophthalmic Drug FDF Production Capacity: Distribution by Geography (Million Units)
Table 19.73 Ophthalmic Drug FDF Production Capacity in North America (Million Units)
Table 19.74 Ophthalmic Drug FDF Production Capacity in Europe (Million Units)
Table 19.75 Ophthalmic Drug FDF Production Capacity in Asia-Pacific (Million Units)
Table 19.76 Ophthalmic Drug FDF Capacity: Distribution by Scale of Operation (Million Units)
Table 19.77 Lab Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.78 Clinical Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.79 Commercial Scale Ophthalmic Drug FDF Production Capacity (Million Units)
Table 19.80 Ophthalmic Drug FDF Capacity: Distribution by Company Size (Million Units)
Table 19.81 Ophthalmic Drug FDF Production Capacity of Small-sized Companies (Million Units)
Table 19.82 Ophthalmic Drug FDF Production Capacity of Mid-sized Companies (Million Units)
Table 19.83 Ophthalmic Drug FDF Production Capacity of Large-sized Companies (Million Units)
Table 19.84 Ophthalmic Drug FDF Capacity: Distribution by Type of Primary Packaging (Million Units)
Table 19.85 Ophthalmic Drug FDF Production Capacity of Ampoules / Vials (Million Units)
Table 19.86 Ophthalmic Drug FDF Production Capacity of Glass / Plastic Bottles (Million Units)
Table 19.87 Ophthalmic Drug FDF Production Capacity of Ointment Tubes (Million Units)
Table 19.88 Overall Commercial Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Table 19.89 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.90 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.91 Commercial Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.92 Overall Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Table 19.93 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.94 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.95 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.96 Commercial Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Type of Primary Packaging (Million Liters)
Table 19.97 Overall Clinical Demand for Ophthalmic API Contract Manufacturing (Million Liters)
Table 19.98 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.99 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.100 Clinical Demand for Ophthalmic API Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.101 Overall Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing (Million Liters)
Table 19.102 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Geography (Million Liters)
Table 19.103 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Scale of Operation (Million Liters)
Table 19.104 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Target Indication (Million Liters)
Table 19.105 Clinical Demand for Ophthalmic Drug FDF Contract Manufacturing: Distribution by Primary Packaging (Million Liters)
Table 19.106 Overall Ophthalmic Drugs Contract Manufacturing: Demand and Supply
Table 19.107 Overall Ophthalmic Drugs Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.108 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Type of Product, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.109 Ophthalmic API Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.110 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.111 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of FDF Manufactured, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.112 Ophthalmic Drugs Contract Manufacturing Market for Solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.113 Ophthalmic Drugs Contract Manufacturing Market for Semi-solids, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.114 Ophthalmic Drugs Contract Manufacturing Market for Liquids / Suspensions, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.115 Ophthalmic Drug FDF Contract Manufacturing Market, 2020-2030: Distribution by Type of Primary Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.116 Ophthalmic Drugs Contract Manufacturing Market for Ampoules / Vials, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.117 Ophthalmic Drugs Contract Manufacturing Market for Glass / Plastic Bottles, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.118 Ophthalmic Drugs Contract Manufacturing Market for Ointment Tubes, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.119 Ophthalmic Drugs Contract Manufacturing Market for Blister Packing, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.120 Ophthalmic Drugs Contract Manufacturing Market for Other Packaging Forms, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.121 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Target Disease Indication, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.122 Ophthalmic Drugs Contract Manufacturing Market for Age-related Macular Degeneration, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.123 Ophthalmic Drugs Contract Manufacturing Market for Dry Eye, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.124 Ophthalmic Drugs Contract Manufacturing Market for Glaucoma, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.125 Ophthalmic Drugs Contract Manufacturing Market for Uveitis, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.126 Ophthalmic Drugs Contract Manufacturing Market for Other Eye Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.127 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.128 Ophthalmic Drugs Contract Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.129 Ophthalmic Drugs Contract Manufacturing Market for Commercial Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.130 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Company Size, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.131 Ophthalmic Drugs Contract Manufacturing Market for Small-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.132 Ophthalmic Drugs Contract Manufacturing Market for Mid-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.133 Ophthalmic Drugs Contract Manufacturing Market for Large-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.134 Ophthalmic Drugs Contract Manufacturing Market, 2020-2030: Distribution by Geographical Regions, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.135 Ophthalmic Drugs Contract Manufacturing Market in North America, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.136 Ophthalmic Drugs Contract Manufacturing Market in the US, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.137 Ophthalmic Drugs Contract Manufacturing Market in Canada, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.138 Ophthalmic Drugs Contract Manufacturing Market in Mexico, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.139 Ophthalmic Drugs Contract Manufacturing Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.140 Ophthalmic Drugs Contract Manufacturing Market in the UK, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.141 Ophthalmic Drugs Contract Manufacturing Market in Germany, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.142 Ophthalmic Drugs Contract Manufacturing Market in France, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.143 Ophthalmic Drugs Contract Manufacturing Market in Spain, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.144 Ophthalmic Drugs Contract Manufacturing Market in Italy, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.145 Ophthalmic Drugs Contract Manufacturing Market in Rest of Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.146 Ophthalmic Drugs Contract Manufacturing Market in Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.147 Ophthalmic Drugs Contract Manufacturing Market in India, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.148 Ophthalmic Drugs Contract Manufacturing Market in China, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.149 Ophthalmic Drugs Contract Manufacturing Market in Japan, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.150 Ophthalmic Drugs Contract Manufacturing Market in Australia, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.151 Ophthalmic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 19.152 Small Molecule Drugs and Biologics: Historical Trend of FDA Approval, 2010-Q3 2019
Table 19.153 Survey Insights: Distribution by Type of Organization
Table 19.154 Survey Insights: Distribution by Location of Organization
Table 19.155 Survey Insights: Distribution by Seniority Level
Table 19.156 Survey Insights: Distribution by Type of Product
Table 19.157 Survey Insights: Distribution by Type of Primary Packaging
Table 19.158 Survey Insights: Distribution by Scale of Operation
Table 19.159 Survey Insights: Distribution by Location of Manufacturing Facilities
Table 19.160 Survey Insights: Distribution by Regulatory Accreditations / Certifications of Manufacturing Facilities
Table 19.161 Survey Insights: Distribution by Extent of Outsourcing
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES